Five things for pharma marketers to know: Tuesday, January 9, 2018
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Payments To Physicians
Five things for pharma marketers to know: Thursday, December 28, 2017
Study: male docs earn more than female peers; new Michigan law tackles opioid crisis; study: some docs billed Medicare for most expensive patient visit type
Five things for pharma marketers to know: Wednesday, December 20, 2017
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Limits on pharma payments to doctors back on policy menu
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Five things for pharma marketers to know: Friday, June 2, 2017
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
Five things for pharma marketers to know: Friday, December 16, 2016
Allergan to settle allegations relating to speakers bureaus; Mylan launches generic version of the EpiPen; 20 states sue six drugmakers accused of price-fixing
Almost one-third of physicians participated in an ACO last year: Medscape
Despite increasing income, many doctors are turning away from self-employment.
Five things for pharma marketers to know: Monday, December 8
Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.
Open Payments website ‘temporarily’ taken offline
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
Doctors want to know how CMS plans to display Sunshine payment data
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
